Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Next Previous
Trial Profile

Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Asthma; Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMETHYST

    • Most Recent Events

    • 08 Mar 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual initiation date changed from Mar 2008 to Jan 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned number of patients changed from 498 to 750 as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top